양성자 펌프 억제제용 오메프라졸 합성

키랄 선택 화학으로 위산 조절하기

Pharmaceutical & Drug Manufacturing Global Industrial Scale $3.5 billion

개요

Omeprazole is the first proton pump inhibitor (PPI) to reach the market and remains one of the most prescribed medications globally for treating gastric acid disorders, peptic ulcers, and GERD. The synthesis involves a multi-step process building the benzimidazole-pyridine core structure. The chiral version, esomeprazole (the S-enantiomer), represents a significant pharmaceutical advancement, produced using an asymmetric oxidation that won AstraZeneca substantial patent protection.

화학 공정

2-Chloromethyl-3,5-dimethyl-4-methoxypyridine is coupled with 5-methoxy-2-mercaptobenzimidazole to form the thioether intermediate. Selective oxidation with m-CPBA or titanium-mediated asymmetric oxidation yields the sulfoxide drug substance.

Thioether intermediate + m-CPBA → Omeprazole (sulfoxide)
For esomeprazole: Ti(OiPr)₄/(R,R)-DET/cumene hydroperoxide → S-omeprazole (>99.5% ee)

원자재

  • 5-Methoxy-2-mercaptobenzimidazole — Multi-step synthesis from o-phenylenediamine (Core structure)
  • 2-Chloromethyl-3,5-dimethyl-4-methoxypyridine — Pyridine chemistry (Pyridine moiety)
  • m-CPBA (meta-chloroperoxybenzoic acid) — Chemical synthesis (Oxidizing agent)

최종 제품

  • Omeprazole (C₁₇H₁₉N₃O₃S) — Proton pump inhibitor for GERD and ulcers (Racemic or enantiopure form)
<path stroke-linecap="round" stroke-linejoin="round" d="M12 9v3.75m-9.303 3.376c-.866 1.5.217 3.374 1.948 3.374h14.71c1.73 0 2.813-1.874 1.948-3.374L13.949 3.378c-.866-1.5-3.032-1.5-3.898 0L2.697 16.126zM12 15.75h.007v.008H12v-.008z" />

Environmental Impact

Multi-step synthesis generates significant organic waste including halogenated solvents. m-CPBA oxidation produces m-chlorobenzoic acid waste. Modern production increasingly uses catalytic oxidation methods and solvent recycling to minimize environmental impact.

안전 고려사항

최근 혁신

Biocatalytic oxidation using engineered cytochrome P450 enzymes and Baeyer-Villiger monooxygenases offers enantioselective sulfoxidation under mild conditions, potentially replacing chemical oxidants entirely.

생산 규모

800

톤/년

$3.5 billion

시장 가치

더 보기: Pharmaceutical & Drug Manufacturing

살리실산의 아세틸화를 통한 아스피린 합성

Global Industrial Scale

메트포르민 염산염 합성

Global Industrial Scale

아목시실린 반합성 생산

Global Industrial Scale

파라세타몰(아세트아미노펜) 합성

Global Industrial Scale

재조합 인간 인슐린 생산

Global Industrial Scale

이부프로펜 합성 — BHC 그린 공정

Global Industrial Scale

발효를 통한 페니실린 G 생산

Global Industrial Scale

Frequently Asked Questions

What industry uses 양성자 펌프 억제제용 오메프라졸 합성?
양성자 펌프 억제제용 오메프라졸 합성 is used in the pharmaceutical & drug manufacturing sector at global industrial scale scale.
What process is involved in 양성자 펌프 억제제용 오메프라졸 합성?
2-Chloromethyl-3,5-dimethyl-4-methoxypyridine is coupled with 5-methoxy-2-mercaptobenzimidazole to form the thioether intermediate. Selective oxidation with m-CPBA or titanium-mediated asymmetric oxidation yields the sulfoxide drug substance.
What is the economic significance of 양성자 펌프 억제제용 오메프라졸 합성?
양성자 펌프 억제제용 오메프라졸 합성 has a market value of $3.5 billion and annual production of 800 tons.
What is the environmental impact of 양성자 펌프 억제제용 오메프라졸 합성?
Multi-step synthesis generates significant organic waste including halogenated solvents. m-CPBA oxidation produces m-chlorobenzoic acid waste. Modern production increasingly uses catalytic oxidation methods and solvent recycling to minimize environmental impact.
What raw materials are used in 양성자 펌프 억제제용 오메프라졸 합성?
The main raw materials include: 5-Methoxy-2-mercaptobenzimidazole, 2-Chloromethyl-3,5-dimethyl-4-methoxypyridine, m-CPBA (meta-chloroperoxybenzoic acid).